Femasys Inc (FEMY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$2.83+5.60%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Femasys is improving its losses, cutting operating losses by $0.4M. It focuses on non-surgical women's health treatments. Analysts expect revenue to grow about 15% next year.
The company is still losing money with no profit yet. Revenue growth may not meet analyst expectations. The stock price has dropped over 55% recently.
The market expects about 15% revenue growth next year. Our fair value is near current price, reflecting high risk and losses.
Breaks if: Company loses Nasdaq listing compliance
Breaks if: Operating loss does not improve by $0.4M or worsens next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
FEMY represents a speculative growth investment with a focus on advancing its fertility and birth control products. The current thesis state indicates volatility in management and recent weak financial performance, which creates uncertainty in the near term.
The market seems to have priced in a low expectations gap, suggesting that FEMY is seen as justified in its valuation despite being loss-making. There is a durable premium compared to peers, indicating that investors may expect some recovery or improvement over time.
Management has made progress on commercialization and reducing losses, but recent financial performance remains weak. The trajectory shows mixed results, with a slight improvement in net income but ongoing losses that could affect future performance.
The thesis hinges on management's ability to maintain cash flow and advance product commercialization. Additionally, external factors like sector performance and economic conditions will play a significant role in shaping FEMY's future.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue growth falls below 15% next year
Over the next 1 to 3 years, FEMY's outlook will depend on its operational execution and market conditions. Not investment advice.